Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5657522 | 0.98 | GLA (0.58) | TDP1CA12CA1CA2CA9 | |
| Formic Acid SCHEMBL3265060 | 0.93 | TDP1 (0.53) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL16932573 | 0.89 | SMN1; SMN2 (0.51) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL76649 | 0.89 | GAA (0.68) | TSHRPOLBHPGDALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5658003 | 0.87 | GAA (0.66) | TSHRPOLBHPGDGLAALDH1A1 | |
| Cyclohexanol SCHEMBL9499559 | 0.86 | EPHX1 (0.52) | TDP1TSHRALDH1A1GAA | |
| SCHEMBL30522606 | 0.86 | TDP1 (0.75) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL3897267 | 0.86 | SMN1; SMN2 (0.60) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL14237141 | 0.86 | TDP1 (0.60) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL21065340 | 0.85 | CA12 (0.48) | CA12CA1CA2CA9POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024107753-A2 | TREATMENT OF ASCT2-DEPENDENT CANCERS | NEUPHARMA, INC (US) | 2024-05-23 | — | — | WO | claimed |
| US-10912784-B2 | Certain chemical entities, compositions, and methods | SUZHOU NEUPHARMA CO., LTD. (CN) | 2021-02-09 | — | — | US | claimed |
| EP-3296313-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | SUZHOU NEUPHARMA CO LTD (CN) | 2020-12-16 | — | — | EP | claimed |
| US-20200354398-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2020-11-12 | — | — | US | claimed |
| EP-3453714-B1 | CARDENOLIDE AND BUFADIENOLIDE 3-CARBONATE AND 3-CARBAMATE DERIVATIVES FOR THE TREATMENT OF CANCER AND COMPOSITIONS THEREOF | SUZHOU NEUPHARMA CO LTD (CN) | 2020-11-04 | — | — | EP | claimed |
| US-10766920-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2020-09-08 | — | — | US | claimed |
| US-20200085846-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | SUZHOU NEUPHARMA CO., LTD. (CN) | 2020-03-19 | — | — | US | claimed |
| US-20200024303-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2020-01-23 | — | — | US | claimed |
| US-10344048-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2019-07-09 | — | — | US | claimed |
| EP-3453714-A2 | CARDENOLIDE AND BUFADIENOLIDE 3-CARBONATE AND 3-CARBAMATE DERIVATIVES FOR THE TREATMENT OF CANCER AND COMPOSITIONS THEREOF | Suzhou Neupharma Co., Ltd (CN) | 2019-03-13 | — | — | EP | claimed |
| CN-103619865-A | Certain chemical entities, compositions, and methods | SUZHOU NEUPHARMA CO LTD | 2014-03-05 | — | — | CN | claimed |
| US-8614211-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2013-12-24 | — | — | US | claimed |
| US-20130040945-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2013-02-14 | — | — | US | claimed |
| WO-2013023145-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-02-14 | — | — | WO | claimed |
| US-20120196842-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2012-08-02 | — | — | US | claimed |
| WO-2012027957-A1 | BUFALIN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | SUZHOU NEUPHARMA CO., LTD. (CN) | 2012-03-08 | — | — | WO | claimed |
| EP-1515724-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-10-21 | — | — | EP | claimed |
| US-20050009809-A1 | Aryl- and heteroaryl-substituted piperazinylcarbonyl acridines and their homologs, e.g., (1,3-dihydroxyacridin-9-yl)-[4-(6-methyl pyridin-2-yl )piperazin-1-yl]methanone,are suitable for treating benign and malignant tumors | ZENTARIS GMBH (DE) | 2005-01-13 | — | — | US | claimed |
| WO-1999012532-A2 | PIPERIDINE DERIVATIVES AGAINST MALARIA | F.HOFFMANN-LA ROCHE AG (CH) | 1999-03-18 | — | — | WO | claimed |
| EP-0671388-B1 | (Pyrrolidinyl)phenyl carbamates and intermediate compounds, processes for their preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (US) | 1998-06-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354398-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TP53, VHL, SGMS2 | TDP1 1779/4885CA12 271/4885CA1 2558/4885 |
| US-20050009809-A1 | Aryl- and heteroaryl-substituted piperazinylcarbonyl acridines and their homologs, e.g., (1,3-dihydroxyacridin-9-yl)-[4-(6-methyl pyridin-2-yl )piperazin-1-yl]methanone,are suitable for treating benign and malignant tumors | PKD1, MDH2, MSH2 | TDP1 2467/4885CA12 4871/4885CA1 4876/4885 |
| US-10912784-B2 | Certain chemical entities, compositions, and methods | UGT2B7, BCCIP, ABCG2 | TDP1 2144/4885CA12 941/4885CA1 2824/4885 |
| US-20120196842-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TP53, VHL, SGMS2 | TDP1 1779/4885CA12 271/4885CA1 2558/4885 |
| US-10766920-B2 | Certain chemical entities, compositions, and methods | TP53, VHL, SGMS2 | TDP1 1779/4885CA12 271/4885CA1 2558/4885 |
| US-20200024303-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TP53, VHL, SGMS2 | TDP1 1779/4885CA12 271/4885CA1 2558/4885 |
| US-20200085846-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | UGT2B7, BCCIP, ABCG2 | TDP1 2144/4885CA12 941/4885CA1 2824/4885 |
| US-20130040945-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | RXRG, ARNT, RARS2 | TDP1 4037/4885CA12 986/4885CA1 2686/4885 |
| US-10344048-B2 | Certain chemical entities, compositions, and methods | TP53, VHL, SGMS2 | TDP1 1779/4885CA12 271/4885CA1 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.